Evidence map›Paper›PMID 35891458›Full record

ArticleViruses2022

HPV16 Induces Formation of Virus-p62-PML Hybrid Bodies to Enable Infection.

Linda Schweiger, Laura A Lelieveld-Fast, Snježana Mikuličić, Johannes Strunk, Kirsten Freitag, Stefan Tenzer, Albrecht M Clement, Luise Florin

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. The Autophagy ReceptorViruses · 2024
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Linda SchweigerInstitute for Virology and Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Obere Zahlbacher Strasse 67, 55131 Mainz, Germany.
Laura A Lelieveld-FastInstitute for Virology and Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Obere Zahlbacher Strasse 67, 55131 Mainz, Germany.ORCID 0000-0002-4041-8917
Snježana MikuličićInstitute for Virology and Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Obere Zahlbacher Strasse 67, 55131 Mainz, Germany.
Johannes StrunkInstitute for Virology and Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Obere Zahlbacher Strasse 67, 55131 Mainz, Germany.ORCID 0000-0003-1675-3421
Kirsten FreitagInstitute for Virology and Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Obere Zahlbacher Strasse 67, 55131 Mainz, Germany.
Stefan TenzerInstitute of Immunology, University Medical Center, Johannes Gutenberg University of Mainz, 55131 Mainz, Germany.ORCID 0000-0003-3034-0017
Albrecht M ClementInstitute of Pathobiochemistry, University Medical Center, Johannes Gutenberg University of Mainz, Duesbergweg 6, 55128 Mainz, Germany.
Luise FlorinInstitute for Virology and Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg University of Mainz, Obere Zahlbacher Strasse 67, 55131 Mainz, Germany.ORCID 0000-0003-4310-7329
Johannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomaviruses (HPVs) inflict a significant burden on the human population. The clinical manifestations caused by high-risk HPV types are cancers at anogenital sites, including cervical cancer, as well as head and neck cancers. Host cell defense mechanisms such as autophagy are initiated upon HPV entry. At the same time, the virus modulates cellular antiviral processes and structures such as promyelocytic leukemia nuclear bodies (PML NBs) to enable infection. Here, we uncover the autophagy adaptor p62, also known as p62/sequestosome-1, as a novel proviral factor in infections by the high-risk HPV type 16 (HPV16). Proteomics, imaging and interaction studies of HPV16 pseudovirus-treated HeLa cells display that p62 is recruited to virus-filled endosomes, interacts with incoming capsids, and accompanies the virus to PML NBs, the sites of viral transcription and replication. Cellular depletion of p62 significantly decreased the delivery of HPV16 viral DNA to PML NBs and HPV16 infection rate. Moreover, the absence of p62 leads to an increase in the targeting of viral components to autophagic structures and enhanced degradation of the viral capsid protein L2. The proviral role of p62 and formation of virus-p62-PML hybrid bodies have also been observed in human primary keratinocytes, the HPV target cells. Together, these findings suggest the previously unrecognized virus-induced formation of p62-PML hybrid bodies as a viral mechanism to subvert the cellular antiviral defense, thus enabling viral gene expression.

Indexed as

Human papillomavirus 16Papillomavirus InfectionsAntiviral AgentsHeLa CellsHumansPapillomaviridaePromyelocytic Leukemia ProteinAntiviral AgentsPromyelocytic Leukemia Proteinantiviral defenseautophagyHPV16human papillomavirushybrid bodiesL2p62promyelocytic leukemia nuclear bodies (PML NB)sequestosome-1

Identifiers

PMID35891458
PMCPMC9315800
OpenAlexW4284878779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.